Positive News SentimentPositive NewsNASDAQ:BCYC Bicycle Therapeutics (BCYC) Stock Price, News & Analysis $7.10 +0.01 (+0.14%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$7.16 +0.06 (+0.77%) As of 08/22/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Bicycle Therapeutics Stock (NASDAQ:BCYC) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Bicycle Therapeutics alerts:Sign Up Key Stats Today's Range$7.07▼$7.3550-Day Range$6.95▼$8.7152-Week Range$6.10▼$28.67Volume210,802 shsAverage Volume265,182 shsMarket Capitalization$491.68 millionP/E RatioN/ADividend YieldN/APrice Target$22.22Consensus RatingModerate Buy Company Overview Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom. Read More Bicycle Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks66th Percentile Overall ScoreBCYC MarketRank™: Bicycle Therapeutics scored higher than 66% of companies evaluated by MarketBeat, and ranked 265th out of 937 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingBicycle Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.70, and is based on 7 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageBicycle Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Bicycle Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Bicycle Therapeutics are expected to decrease in the coming year, from ($3.06) to ($3.56) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Bicycle Therapeutics is -2.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Bicycle Therapeutics is -2.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBicycle Therapeutics has a P/B Ratio of 0.62. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Bicycle Therapeutics' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.11% of the float of Bicycle Therapeutics has been sold short.Short Interest Ratio / Days to CoverBicycle Therapeutics has a short interest ratio ("days to cover") of 5.8.Change versus previous monthShort interest in Bicycle Therapeutics has recently decreased by 23.50%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBicycle Therapeutics does not currently pay a dividend.Dividend GrowthBicycle Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.11% of the float of Bicycle Therapeutics has been sold short.Short Interest Ratio / Days to CoverBicycle Therapeutics has a short interest ratio ("days to cover") of 5.8.Change versus previous monthShort interest in Bicycle Therapeutics has recently decreased by 23.50%, indicating that investor sentiment is improving significantly. News and Social Media3.2 / 5News Sentiment1.69 News SentimentBicycle Therapeutics has a news sentiment score of 1.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Bicycle Therapeutics this week, compared to 5 articles on an average week.Search Interest3 people have searched for BCYC on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Bicycle Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $58,820.00 in company stock.Percentage Held by InsidersOnly 8.50% of the stock of Bicycle Therapeutics is held by insiders.Percentage Held by Institutions86.15% of the stock of Bicycle Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Bicycle Therapeutics' insider trading history. Receive BCYC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bicycle Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address BCYC Stock News HeadlinesJMP Securities Cuts Bicycle Therapeutics (NASDAQ:BCYC) Price Target to $10.00August 14, 2025 | americanbankingnews.comOppenheimer Reaffirms "Outperform" Rating for Bicycle Therapeutics (NASDAQ:BCYC)August 14, 2025 | americanbankingnews.comThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profitable trends in tech … well ahead of Wall Street. Like when he called Nvidia at a mere 80 cents a share. Or Bitcoin when it was trading for just $300. Throughout his illustrious career … Michael has given his followers almost 150 different chances to register triple-digit gains.August 24 at 2:00 AM | Weiss Ratings (Ad)Equities Analysts Offer Predictions for BCYC Q3 EarningsAugust 14, 2025 | americanbankingnews.comBicycle Therapeutics plc (NASDAQ:BCYC) Analysts Are Cutting Their Estimates: Here's What You Need To KnowAugust 14, 2025 | finance.yahoo.comBicycle Therapeutics price target lowered to $10 from $22 at Citizens JMPAugust 12, 2025 | msn.comNeed To Know: The Consensus Just Cut Its Bicycle Therapeutics plc (NASDAQ:BCYC) Estimates For 2025August 10, 2025 | finance.yahoo.comBicycle (BCYC) Q2 Revenue Falls 69%August 9, 2025 | theglobeandmail.comSee More Headlines BCYC Stock Analysis - Frequently Asked Questions How have BCYC shares performed this year? Bicycle Therapeutics' stock was trading at $14.00 at the beginning of the year. Since then, BCYC shares have decreased by 49.3% and is now trading at $7.10. How were Bicycle Therapeutics' earnings last quarter? Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) released its quarterly earnings results on Friday, August, 8th. The company reported ($1.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.95) by $0.19. The business had revenue of $2.90 million for the quarter, compared to analysts' expectations of $9.43 million. Bicycle Therapeutics had a negative net margin of 1,257.00% and a negative trailing twelve-month return on equity of 32.43%. When did Bicycle Therapeutics IPO? Bicycle Therapeutics (BCYC) raised $64 million in an initial public offering (IPO) on Thursday, May 23rd 2019. The company issued 4,300,000 shares at a price of $14.00-$16.00 per share. Goldman Sachs, Jefferies and Piper Jaffray served as the underwriters for the IPO and Canaccord Genuity was co-manager. Who are Bicycle Therapeutics' major shareholders? Bicycle Therapeutics' top institutional shareholders include Armistice Capital LLC (4.04%), Westfield Capital Management Co. LP (4.02%), Candriam S.C.A. (1.69%) and Tybourne Capital Management HK Ltd. (1.44%). Insiders that own company stock include Bros Advisors Lp Baker, Kevin Lee, Michael Skynner, Alistair Milnes, Santiago Arroyo, Nicholas Keen, Michael Charles Ferguso Hannay, Nigel Crockett, Alethia Young, Travis Alvin Thompson and Lee Kalowski. View institutional ownership trends. How do I buy shares of Bicycle Therapeutics? Shares of BCYC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Bicycle Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Bicycle Therapeutics investors own include Vale (VALE), uniQure (QURE), Clean Energy Fuels (CLNE), Paycom Software (PAYC), Grayscale Ethereum Trust (ETH) (ETHE), Curaleaf (CURLF) and Marathon Oil (MRO). Company Calendar Last Earnings8/08/2025Today8/24/2025Next Earnings (Estimated)10/30/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BCYC CIK1761612 Webwww.bicycletherapeutics.com Phone441223261503FaxN/AEmployees240Year FoundedN/APrice Target and Rating Average Price Target for Bicycle Therapeutics$22.22 High Price Target$44.00 Low Price Target$10.00 Potential Upside/Downside+213.0%Consensus RatingModerate Buy Rating Score (0-4)2.70 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($3.51) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$169.03 million Net Margins-1,257.00% Pretax Margin-1,287.33% Return on Equity-32.43% Return on Assets-26.80% Debt Debt-to-Equity RatioN/A Current Ratio10.39 Quick Ratio10.39 Sales & Book Value Annual Sales$35.28 million Price / Sales13.94 Cash FlowN/A Price / Cash FlowN/A Book Value$9.66 per share Price / Book0.73Miscellaneous Outstanding Shares69,250,000Free Float53,395,000Market Cap$491.68 million OptionableOptionable Beta1.44 Social Links 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:BCYC) was last updated on 8/24/2025 by MarketBeat.com Staff From Our PartnersIs This Stock the 'Next Nvidia'?'AI Bottleneck' Now Threatens Entire Magnificent 7 A new critical failure has appeared in the AI market, an...Altimetry | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredTrump’s “new dollar” could shock Americans"I Made Millions in the Tech Boom. Here's Where I'd Put My Money Today" This man has called some of the big...Stansberry Research | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.On a quiet Friday afternoon, one trader spotted an overlooked stock. He bought shares. He shut down his ...Timothy Sykes | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bicycle Therapeutics PLC Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Bicycle Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.